These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma.
    Author: Xia Y, Li ZM, Shi YX, Xia ZJ, Jiang WQ, Huang HQ.
    Journal: Ai Zheng; 2009 Feb; 28(2):146-9. PubMed ID: 19550126.
    Abstract:
    BACKGROUND AND OBJECTIVE: Diffuse large B-cell lymphoma (DLBCL) can be divided into two subgroups as germinal center B-cell like (GCB) and non-GCB DLBCL, according to the origin of tumor cells. The prognosis of GCB DLBCL is better than that of non-GCB DLBCL after receiving the CHOP regimen on initial therapy. This study was to compare the short-term efficacy of rituximab(R)-CHOP and CHOP regimens on GCB and non-GCB DLBCL, thus to explore the optimal first-line regimen for the initial treatment of DLBCL patients. METHODS: In total, eighty-three patients with de novo DLBCL initially treated at Sun Yat-sen University Cancer Center from November 2006 to February 2008 were enrolled. Patients were divided into GCB and non-GCB groups. The short-term efficacy of the CHOP or R-CHOP regimen as the first-line therapy on the two groups was evaluated according to the revised response criteria for lymphoma. Bcl-2 expression and its correlation to the short-term efficacy of the two groups were assessed. RESULTS: There were 35 cases (42.2%) in the GCB group and 48 cases (57.8%) in the non-GCB group. The total remission rate was 74.3% in the GCB group and 60.4% in the non-GCB group (p = 0.006). There was no significant difference in Bcl-2 expression in the two groups. The remission rate was higher in Bcl-2 positive patients receiving R-CHOP regimen than those receiving CHOP regimen (75.6% vs. 47.8%, p = 0.023). There was no significant difference in the remission rate of Bcl-2 negative patients, regardless of chemotherapy regimen. CONCLUSION: The prognosis is better in the GCB group than in the non-GCB group. Addition of rituximab to CHOP could improve the short-term efficacy of Bcl-2 positive patients.
    [Abstract] [Full Text] [Related] [New Search]